Sorrento Therapeutics (LTS:0L85) LT-Debt-to-Total-Asset: 0.16 (As of Jun. 2023)


LTS:0L85 Sorrento Therapeutics Inc LTS:0L85
12 GF Score
Price $0.00
View Full Analysis

What is Sorrento Therapeutics LT-Debt-to-Total-Asset?

Sorrento Therapeutics LTS:0L85 12 LT-Debt-to-Total-Asset is 0.16 as of Jun. 2023. GuruFocus rates LTS:0L85 with a GF Score™ of 12/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Sorrento Therapeutics's long-term debt to total assests ratio for the quarter that ended in Jun. 2023 was 0.16.

Sorrento Therapeutics's long-term debt to total assets ratio declined from Jun. 2022 (0.27) to Jun. 2023 (0.16). It may suggest that Sorrento Therapeutics is progressively becoming less dependent on debt to grow their business.

Sorrento Therapeutics  (LTS:0L85) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Sorrento Therapeutics LT-Debt-to-Total-Asset Related Terms

Sorrento Therapeutics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Sorrento Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics LT-Debt-to-Total-Asset Chart

Sorrento Therapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.36 0.45 0.27 0.28 0.22

Sorrento Therapeutics Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.17 0.22 0.23 0.16
LTS:0L85
12GF Score
Sorrento Therapeutics Inc LTS:0L85
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sorrento Therapeutics LT-Debt-to-Total-Asset Calculation

Sorrento Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

LT Debt to Total Assets (A: Dec. 2022 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2022 )/Total Assets (A: Dec. 2022 )
=104.338/472.84
=0.22

Sorrento Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

LT Debt to Total Assets (Q: Jun. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2023 )/Total Assets (Q: Jun. 2023 )
=74.187/456.692
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.16 mean?
Sorrento Therapeutics (LTS:0L85) has a LT-Debt-to-Total-Asset of 0.16 as of Jun. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sorrento Therapeutics and its competitors.
Is Sorrento Therapeutics' LT-Debt-to-Total-Asset too high?
Sorrento Therapeutics' current LT-Debt-to-Total-Asset is 0.16. Overall, Sorrento Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sorrento Therapeutics' LT-Debt-to-Total-Asset compare to IMUX and OCUP?
Sorrento Therapeutics' LT-Debt-to-Total-Asset of 0.16 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Sorrento Therapeutics and its competitors. Sorrento Therapeutics's current LT-Debt-to-Total-Asset is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sorrento Therapeutics stock overvalued right now?
Sorrento Therapeutics (LTS:0L85) has a current LT-Debt-to-Total-Asset of 0.16. The current LT-Debt-to-Total-Asset is 0.16. Sorrento Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Sorrento Therapeutics (LTS:0L85), the current LT-Debt-to-Total-Asset is 0.16 as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sorrento Therapeutics Business Description

Address 4955 Directors Place, San Diego, CA, USA, 92121
Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.
12GF Score

Get the complete analysis for LTS:0L85

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price